Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARD3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARD3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARD3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PARD3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARD3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PARD3_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARD3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PARD3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARD3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARD3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARD3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARD3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006156416 | Skin | AK | axon development | 91/1910 | 467/18723 | 8.60e-10 | 8.63e-08 | 91 |
GO:000716326 | Skin | AK | establishment or maintenance of cell polarity | 53/1910 | 218/18723 | 1.32e-09 | 1.26e-07 | 53 |
GO:000740916 | Skin | AK | axonogenesis | 80/1910 | 418/18723 | 2.07e-08 | 1.19e-06 | 80 |
GO:003001019 | Skin | AK | establishment of cell polarity | 36/1910 | 143/18723 | 2.24e-07 | 9.02e-06 | 36 |
GO:000704319 | Skin | AK | cell-cell junction assembly | 36/1910 | 146/18723 | 3.88e-07 | 1.47e-05 | 36 |
GO:005165618 | Skin | AK | establishment of organelle localization | 69/1910 | 390/18723 | 3.69e-06 | 9.11e-05 | 69 |
GO:00519607 | Skin | AK | regulation of nervous system development | 72/1910 | 443/18723 | 4.53e-05 | 7.11e-04 | 72 |
GO:00420637 | Skin | AK | gliogenesis | 53/1910 | 301/18723 | 5.42e-05 | 8.29e-04 | 53 |
GO:000660526 | Skin | AK | protein targeting | 53/1910 | 314/18723 | 1.67e-04 | 1.94e-03 | 53 |
GO:00516429 | Skin | AK | centrosome localization | 11/1910 | 32/18723 | 2.05e-04 | 2.31e-03 | 11 |
GO:004593627 | Skin | AK | negative regulation of phosphate metabolic process | 69/1910 | 441/18723 | 2.08e-04 | 2.34e-03 | 69 |
GO:001056327 | Skin | AK | negative regulation of phosphorus metabolic process | 69/1910 | 442/18723 | 2.22e-04 | 2.47e-03 | 69 |
GO:00350889 | Skin | AK | establishment or maintenance of apical/basal cell polarity | 14/1910 | 49/18723 | 2.72e-04 | 2.89e-03 | 14 |
GO:00612459 | Skin | AK | establishment or maintenance of bipolar cell polarity | 14/1910 | 49/18723 | 2.72e-04 | 2.89e-03 | 14 |
GO:00618429 | Skin | AK | microtubule organizing center localization | 11/1910 | 33/18723 | 2.79e-04 | 2.94e-03 | 11 |
GO:009015023 | Skin | AK | establishment of protein localization to membrane | 45/1910 | 260/18723 | 2.84e-04 | 2.99e-03 | 45 |
GO:00100017 | Skin | AK | glial cell differentiation | 40/1910 | 225/18723 | 3.45e-04 | 3.47e-03 | 40 |
GO:00425525 | Skin | AK | myelination | 27/1910 | 134/18723 | 4.20e-04 | 4.00e-03 | 27 |
GO:00072725 | Skin | AK | ensheathment of neurons | 27/1910 | 136/18723 | 5.36e-04 | 4.85e-03 | 27 |
GO:00083665 | Skin | AK | axon ensheathment | 27/1910 | 136/18723 | 5.36e-04 | 4.85e-03 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARD3 | SNV | Missense_Mutation | | c.3714N>G | p.Asp1238Glu | p.D1238E | Q8TEW0 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.99) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PARD3 | SNV | Missense_Mutation | rs566752362 | c.2728N>T | p.Arg910Cys | p.R910C | Q8TEW0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
PARD3 | SNV | Missense_Mutation | | c.1741N>A | p.Asp581Asn | p.D581N | Q8TEW0 | protein_coding | deleterious(0.03) | benign(0.116) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PARD3 | SNV | Missense_Mutation | | c.2826N>A | p.Asp942Glu | p.D942E | Q8TEW0 | protein_coding | tolerated(0.12) | probably_damaging(0.992) | TCGA-E2-A15T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARD3 | insertion | Frame_Shift_Ins | novel | c.3814_3815insTTTTTTTAAAACCTCGATGGTACTATGGAGTATTTCTGTTGTT | p.Gly1272ValfsTer54 | p.G1272Vfs*54 | Q8TEW0 | protein_coding | | | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
PARD3 | insertion | Nonsense_Mutation | novel | c.1625_1626insATTAATTATACAAATATAGGTCTTGTTACTTAGGATGACA | p.Val544IlefsTer5 | p.V544Ifs*5 | Q8TEW0 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARD3 | SNV | Missense_Mutation | rs768549956 | c.3613C>T | p.Arg1205Trp | p.R1205W | Q8TEW0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.928) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARD3 | SNV | Missense_Mutation | novel | c.2885C>A | p.Ser962Tyr | p.S962Y | Q8TEW0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARD3 | SNV | Missense_Mutation | | c.3253G>C | p.Asp1085His | p.D1085H | Q8TEW0 | protein_coding | tolerated(0.12) | probably_damaging(0.999) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
PARD3 | SNV | Missense_Mutation | rs377613171 | c.3701C>T | p.Ser1234Leu | p.S1234L | Q8TEW0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.124) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |